TAMSULOSIN CR 0.4 MG
TAMSULOSIN HYDROCHLORIDE : 0.4 MG · DIN 02429667 · SIVEM PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is TAMSULOSIN CR?
TAMSULOSIN CR 0.4 MG contains TAMSULOSIN HYDROCHLORIDE : 0.4 MG. It is listed in the Health Canada Drug Product Database under DIN 02429667, held by SIVEM PHARMACEUTICALS ULC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Oct-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TAMSULOSIN CR used for?
Treatment of Lower Urinary Tract Symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02429667 |
|---|---|
| Brand name | TAMSULOSIN CR |
| Generic / active ingredient | TAMSULOSIN HYDROCHLORIDE : 0.4 MG |
| Manufacturer | SIVEM PHARMACEUTICALS ULC |
| Strength | 0.4 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04CA02 TAMSULOSIN |
| AHFS class | 12:16.04.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Oct-2014 |
| Original market date | 2014-10-08 00:00:00 |
How is it administered?
0.4 mg once daily at the same time each day, with or without food. Tablets must be swallowed whole; do not crush or chew.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated). Standard practice is 15-30°C.
How is it supplied?
HDPE bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity to tamsulosin or any component; concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole).
Warnings and precautions
Risk of orthostatic hypotension and syncope. Rule out prostate carcinoma. Risk of Intraoperative Floppy Iris Syndrome (IFIS) during eye surgery. Potential for priapism.
What can be used instead?
Other Canadian products sharing ATC code G04CA02 TAMSULOSIN. 9 of 18 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02362406 |
| AURO-TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | AURO PHARMA INC | MARKETED | DIN 02545179 |
| JAMP TAMSULOSIN | 0.4 MG | CAPSULE (SUSTAINED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02352419 |
| SANDOZ TAMSULOSIN | 0.4 MG | CAPSULE (SUSTAINED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02319217 |
| SANDOZ TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02340208 |
| TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 02413612 |
| TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02427117 |
| TEVA-TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02368242 |
| AVA-TAMSULOSIN CR | 0.4 MG | TABLET (EXTENDED-RELEASE) | AVANSTRA INC | CANCELLED POST MARKET | DIN 02366231 |
| FLOMAX | 0.4 MG | CAPSULE (SUSTAINED-RELEASE) | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | DIN 02238123 |
Who else supplies TAMSULOSIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TAMSULOSIN appears in 192 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.